High-Dose-Rate Brachytherapy and External-Beam Radiotherapy for Hormone-Naieve Low- and Intermediate-Risk Prostate Cancer: A 7-Year Experience

Journal Article · Wed Aug 01 04:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2011.10.055· OSTI ID:22149395

Aluwini, Shafak ^[1]; Rooij, Peter H. van ^[1]; Kirkels, Wim J. ^[2]; Jansen, Peter P.; Praag, John O. ^[1]; Bangma, Chris H. ^[2]; Kolkman-Deurloo, Inger-Karine K. ^[1]

---

1. Department of Radiation Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam (Netherlands)
2. Department of Urology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam (Netherlands)

Purpose: To report clinical outcomes and early and late complications in 264 hormone-naieve patients with low- and intermediate-risk prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) in combination with external-beam radiotherapy (EBRT). Methods and Materials: Between February 2000 and July 2007, 264 patients underwent HDR-BT in combination with EBRT as a treatment for their low- to intermediate-risk prostate cancer. The HDR-BT was performed using ultrasound-based implantation. The total HDR-BT dose was 18 Gy in 3 fractions within 24 h, with a 6-h minimum interval. The EBRT started 2 weeks after HDR-BT and was delivered in 25 fractions of 1.8 Gy to 45 Gy within 5 weeks. Results: After a mean follow-up of 74.5 months, 4 patients (1.5%) showed prostate-specific antigen progression according to the American Society for Radiation Oncology definition and 8 patients (3%) according to the Phoenix definition. A biopsy-proven local recurrence was registered in 1 patient (0.4%), and clinical progression (bone metastases) was documented in 2 patients (0.7%). Seven-year actuarial freedom from biochemical failure was 97%, and 7-year disease-specific survival and overall survival were 100% and 91%, respectively. Toxicities were comparable to other series. Conclusions: Treatment with interstitial HDR-BT plus EBRT shows a low incidence of late complications and a favorable oncologic outcome after 7 years follow-up.

• OSTI ID: 22149395
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 83; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIGENS
BIOPSY
BRACHYTHERAPY
DOSE RATES
FAILURES
HEALTH HAZARDS
HORMONES
METASTASES
NEOPLASMS
PATIENTS
PROSTATE
RADIATION DOSES
SKELETON
TOXICITY